Patents by Inventor Michael D. Gunn

Michael D. Gunn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11684662
    Abstract: Pre-conditioning a vaccine site with a potent recall antigen such as tetanus/diphtheria (Td) toxoid can significantly improve the lymph node homing and efficacy of tumor antigen-specific DC vaccines. Patients given Td had enhanced DC migration bilaterally and significantly improved survival. In mice, Td pre-conditioning also enhanced bilateral DC migration and suppressed tumor growth in a manner dependent on the chemokines CCL3 and CCL21 and Td-activated CD4+ T cells. Interference with any component of this axis markedly reduced Td-mediated DC migration and antitumor responses. Our clinical studies and corroborating investigations in mice suggest that pre-conditioning with a potent recall antigen represents a viable strategy to increase DC homing to lymph nodes and improve antitumor immunotherapy.
    Type: Grant
    Filed: July 11, 2021
    Date of Patent: June 27, 2023
    Assignee: Duke University
    Inventors: John H Sampson, Duane A Mitchell, Kristen A Batich, Michael D Gunn
  • Publication number: 20220031827
    Abstract: Pre-conditioning a vaccine site with a potent recall antigen such as tetanus/diphtheria (Td) toxoid can significantly improve the lymph node homing and efficacy of tumor antigen-specific DC vaccines. Patients given Td had enhanced DC migration bilaterally and significantly improved survival. In mice, Td pre-conditioning also enhanced bilateral DC migration and suppressed tumor growth in a manner dependent on the chemokines CCL3 and CCL21 and Td-activated CD4+ T cells. Interference with any component of this axis markedly reduced Td-mediated DC migration and antitumor responses. Our clinical studies and corroborating investigations in mice suggest that pre-conditioning with a potent recall antigen represents a viable strategy to increase DC homing to lymph nodes and improve antitumor immunotherapy.
    Type: Application
    Filed: July 11, 2021
    Publication date: February 3, 2022
    Applicant: Duke University
    Inventors: John H Sampson, Duane A Mitchell, Kristen A Batich, Michael D Gunn
  • Patent number: 11071777
    Abstract: Pre-conditioning a vaccine site with a potent recall antigen such as tetanus/diphtheria (Td) toxoid can significantly improve the lymph node homing and efficacy of tumor antigen-specific DC vaccines. Patients given Td had enhanced DC migration bilaterally and significantly improved survival. In mice, Td pre-conditioning also enhanced bilateral DC migration and suppressed tumor growth in a manner dependent on the chemokines CCL3 and CCL21 and Td-activated CD4+ T cells. Interference with any component of this axis markedly reduced Td-mediated DC migration and antitumor responses. Our clinical studies and corroborating investigations in mice suggest that pre-conditioning with a potent recall antigen represents a viable strategy to increase DC homing to lymph nodes and improve antitumor immunotherapy.
    Type: Grant
    Filed: April 19, 2018
    Date of Patent: July 27, 2021
    Assignee: Duke University
    Inventors: John H. Sampson, Duane A. Mitchell, Kristen A. Batich, Michael D. Gunn
  • Publication number: 20190381158
    Abstract: Methods of generating an autologous cellular vaccine comprising monocytes or neutrophils and an antigenic polypeptide or nucleotide encoding the antigenic polypeptide are provided. The antigen-loaded cell-based vaccine compositions made using these methods are also provided. Methods of using the antigen-loaded cell-based vaccine compositions are also provided and these vaccines may be used to treat cancer. Kits for carrying out the methods described herein are also provided.
    Type: Application
    Filed: February 3, 2017
    Publication date: December 19, 2019
    Applicant: Duke University
    Inventor: Michael D. Gunn
  • Publication number: 20190060265
    Abstract: A method of treating acute lung injury (ALI) in a patient suspected of having ALI is disclosed. The method includes administering to the patient a therapeutically effective amount of an inducible nitric oxide synthase (iNOS) inhibitor.
    Type: Application
    Filed: February 23, 2018
    Publication date: February 28, 2019
    Inventor: Michael D. Gunn
  • Publication number: 20180236054
    Abstract: Pre-conditioning a vaccine site with a potent recall antigen such as tetanus/diphtheria (Td) toxoid can significantly improve the lymph node homing and efficacy of tumor antigen-specific DC vaccines. Patients given Td had enhanced DC migration bilaterally and significantly improved survival. In mice, Td pre-conditioning also enhanced bilateral DC migration and suppressed tumor growth in a manner dependent on the chemokines CCL3 and CCL21 and Td-activated CD4+ T cells. Interference with any component of this axis markedly reduced Td-mediated DC migration and antitumor responses. Our clinical studies and corroborating investigations in mice suggest that pre-conditioning with a potent recall antigen represents a viable strategy to increase DC homing to lymph nodes and improve antitumor immunotherapy.
    Type: Application
    Filed: April 19, 2018
    Publication date: August 23, 2018
    Applicant: Duke University
    Inventors: John H. Sampson, Duane A. Mitchell, Kristen A. Batich, Michael D. Gunn
  • Patent number: 9974848
    Abstract: Pre-conditioning a vaccine site with a potent recall antigen such as tetanus/diphtheria (Td) toxoid can significantly improve the lymph node homing and efficacy of tumor antigen-specific DC vaccines. Patients given Td had enhanced DC migration bilaterally and significantly improved survival. In mice, Td pre-conditioning also enhanced bilateral DC migration and suppressed tumor growth in a manner dependent on the chemokines CCL3 and CCL21 and Td-activated CD4+ T cells. Interference with any component of this axis markedly reduced Td-mediated DC migration and antitumor responses. Our clinical studies and corroborating investigations in mice suggest that pre-conditioning with a potent recall antigen represents a viable strategy to increase DC homing to lymph nodes and improve antitumor immunotherapy.
    Type: Grant
    Filed: November 14, 2014
    Date of Patent: May 22, 2018
    Assignee: Duke University
    Inventors: John H. Sampson, Duane A. Mitchell, Kristen A. Batich, Michael D. Gunn
  • Patent number: 9901560
    Abstract: A method of treating acute lung injury (ALI) in a patient suspected of having ALI is disclosed. The method includes administering to the patient a therapeutically effective amount of an inducible nitric oxide synthase (iNOS) inhibitor.
    Type: Grant
    Filed: December 14, 2016
    Date of Patent: February 27, 2018
    Assignee: Duke University
    Inventor: Michael D. Gunn
  • Publication number: 20170165216
    Abstract: A method of treating acute lung injury (ALI) in a patient suspected of having ALI is disclosed. The method includes administering to the patient a therapeutically effective amount of an inducible nitric oxide synthase (iNOS) inhibitor.
    Type: Application
    Filed: December 14, 2016
    Publication date: June 15, 2017
    Inventor: Michael D. Gunn
  • Publication number: 20160271240
    Abstract: Pre-conditioning a vaccine site with a potent recall antigen such as tetanus/diphtheria (Td) toxoid can significantly improve the lymph node homing and efficacy of tumor antigen-specific DC vaccines. Patients given Td had enhanced DC migration bilaterally and significantly improved survival. In mice, Td pre-conditioning also enhanced bilateral DC migration and suppressed tumor growth in a manner dependent on the chemokines CCL3 and CCL21 and Td-activated CD4+ T cells. Interference with any component of this axis markedly reduced Td-mediated DC migration and antitumor responses. Our clinical studies and corroborating investigations in mice suggest that pre-conditioning with a potent recall antigen represents a viable strategy to increase DC homing to lymph nodes and improve antitumor immunotherapy.
    Type: Application
    Filed: November 14, 2015
    Publication date: September 22, 2016
    Applicant: Duke University
    Inventors: John H. Sampson, Duane A. Mitchell, Kristen A. Batich, Michael D. Gunn